{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG" in comments (approximate match)
Status:
Investigational
Source:
NCT02573324: Phase 3 Interventional Completed Glioblastoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04311697: Phase 2/Phase 3 Interventional Completed Critical COVID-19 With Respiratory Failure
(2020)
Source URL:
Class:
PROTEIN
Aviptadil, a vasoactive intestinal polypeptide, is a vasodilator and lowers blood pressure if administered intravenously. In 2007, the orphan designation was granted by the European Commission for aviptadil for the treatment of sarcoidosis, a disease of unknown cause that affects many organs and tissues, most commonly the lungs. Sarcoidosis is characterized by specific microscopic lesions called granulomas. Aviptadil is able to influence the immune system that decreases the inflammatory processes seen in sarcoidosis by acting on the white blood cells (lymphocytes and monocytes) involved in the formation of the granulomas. In combination with phentolamine, the drug is used to treat erectile dysfunction. In addition, aviptadil has been studied in phase II clinical trials for patients with respiratory distress syndrome.
Status:
Investigational
Source:
NCT02324049: Phase 1/Phase 2 Interventional Completed Mucopolysaccharidosis IIIB
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02414841: Phase 3 Interventional Completed Chronic Kidney Disease
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03921528: Phase 2 Interventional Completed Spinal Muscular Atrophy
(2019)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT00072930: Phase 2 Interventional Completed Prostate Cancer
(2003)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01123083: Phase 3 Interventional Completed Diabetes Mellitus, Type 1
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03275103: Phase 1 Interventional Active, not recruiting Multiple Myeloma
(2017)
Source URL:
Class:
PROTEIN
